The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bioasborbabletx.com

Total Raised

$9M

Investors Count

8

Deal Terms

1

Bioabsorbable Therapeutics Funding, Bioabsorbable Therapeutics Valuation & Bioabsorbable Therapeutics Revenue

5 Fundings

Bioabsorbable Therapeutics's latest funding round was a Acquired for on October 22, 2010.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/22/2010

Acquired

0

FY undefined

1

2/4/2010

Angel

0

FY undefined

0

5/8/2007

Series B

$99M

0

FY undefined

0

1/23/2006

Series A

0

FY undefined

0

Other Investors

0

FY undefined

0

Date

10/22/2010

2/4/2010

5/8/2007

1/23/2006

Round

Acquired

Angel

Series B

Series A

Other Investors

Amount

$99M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

0

0

Bioabsorbable Therapeutics Deal Terms

1 Deal Term

Bioabsorbable Therapeutics's deal structure is available for 1 funding round, including their Series B from May 08, 2007.

Round

Series B

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Bioabsorbable Therapeutics Investors

8 Investors

Bioabsorbable Therapeutics has 8 investors. MultiCell Technologies invested in Bioabsorbable Therapeutics's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/22/2010

10/22/2010

1
Acquired

Corporation

Rhode Island

00/00/0000

00/00/0000

Life Science Angels

Subscribe to see more

Angel Investor (Group)

California

00/00/0000

00/00/0000

BioStar Capital

Subscribe to see more

Venture Capital

Michigan

00/00/0000

00/00/0000

MedFocus Fund

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Synergy Partners International

Subscribe to see more

Venture Capital

California

First funding

10/22/2010

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

10/22/2010

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Life Science Angels

BioStar Capital

MedFocus Fund

Synergy Partners International

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Angel Investor (Group)

Venture Capital

Venture Capital

Venture Capital

Location

Rhode Island

California

Michigan

California

California

You May Also Like

D
Devices for Vascular Intervention

Devices for Vascular Interventions offers atherectomy systems for removal of plaque from coronary arteries

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

R
Reva Medical

Founded in 1998, REVA Medical is dedicated to developing interventional medical devices that leverage the Company's stent designs and biomaterials to improve the treatment of vascular disease. nnThe Company's flagship product is a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product promises to revolutionize the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The Company is also certified to the ISO 13485:2003 standard.

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

M
Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

T
TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.